Skip to content
Screener

D&A at other companies

Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$102K-42.0%
Cytokinetics logo
CytokineticsCYTK
$3.63M+58.9%
Abbott logo
AbbottABT
$658M+56.7%
Medtronic logo
MedtronicMDT
$716M-14.8%
Savara logo
SavaraSVRA
$28K-17.6%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$4M

Segments

By segment

See full
All Other Segments$4.37M+340%

Other financials

Income statement

See full
Revenue$109.4M+42.9%
Gross profit$95.0M+32.0%
Operating income-$350.0K-107%
Net income-$19.0M-2,949%
EPS (diluted)-$0.06

Balance sheet

See full
Cash & equivalents$52.9M-7.2%
Total debt$11.8M-7.5%
Total equity-$67.2M-22.1%
Total assets$732.3M+77.9%

Cash flow

See full
Operating cash flow-$18.4M-305%
CapEx$5.1M+355%
Free cash flow-$23.5M-399%

Valuation

See full
Market cap$1.26B+20.4%
Enterprise value$1.22B+21.6%
P/S3.2×-0.3×

Profitability

See full
Gross margin89.8%-4.8pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity44.2%
Debt / equity-0.2×
Current ratio1.7×-0.8×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The source filing: Mannkind’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335054
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cost of revenue – collaborations and services15,13115,96125,09429,709
Research and development18,00113,67535,23224,697
Selling, general and administrative58,30231,622112,38956,636
Amortization of acquired intangible assets4,3678,734
(Gain) loss on foreign currency transaction(486)5,363(1,804)7,872
Total expenses109,72471,228201,562127,289
(Loss) income from operations(350)5,299(2,018)27,592
Other income (expense):

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Mannkind's D&A?
Mannkind (MNKD) reported D&A of $4.37M in Q2 2026.
How has Mannkind's D&A changed year-over-year?
Mannkind's D&A increased by 339.7% year-over-year, from $993.25K to $4.37M.
What is the long-term trend for Mannkind's D&A?
Over 3 years (2022 to 2025), Mannkind's D&A has grown at a 6.1% compound annual growth rate (CAGR), from $3.33M to $3.97M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Ask your AI about Mannkind's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude